developed a PSMA monoclonal antibody-modified nanoscale UCAs and showed they could specifically bind to PCa cells in vitro and could significantly increase peak intensity and duration of contrast enhancement than blank NBs in transplanted prostate tumors41. The gene discussed is FOLH1; the disease is posterior cortical atrophy.